-
-
-
-
-
-
-
U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir
-
-
-
-
-
-
-
TD Cowen on Gilead Sciences (GILD): 'We Are Excited By Gilead's Recent String Of Deals'
-
-
-
-
-
-
-
Gilead Extends Tender Offer to Acquire Arcellx
-
-
-
-
-
-
-
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
-
-
-
-
-
-
-
Raymond James on Legend Biotech Corp. (LEGN): 'Arcellx Takeout Indicates Legend is Hugely Undervalued'
-
-
-
-
-
-
-
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
-
-
-
-
-
-
-
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial
-
1,157,739 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

